Compare TBPH & DAO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TBPH | DAO |
|---|---|---|
| Founded | 2013 | 2006 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Consumer Services |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.2B |
| IPO Year | 2013 | 2019 |
| Metric | TBPH | DAO |
|---|---|---|
| Price | $13.86 | $10.18 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $18.50 | N/A |
| AVG Volume (30 Days) | ★ 782.6K | 75.8K |
| Earning Date | 05-07-2026 | 02-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.88 | N/A |
| Revenue | ★ $15,386,000.00 | N/A |
| Revenue This Year | $70.90 | $12.15 |
| Revenue Next Year | N/A | $14.03 |
| P/E Ratio | ★ $15.75 | $72.35 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.90 | $6.30 |
| 52 Week High | $21.03 | $12.96 |
| Indicator | TBPH | DAO |
|---|---|---|
| Relative Strength Index (RSI) | 27.74 | 50.59 |
| Support Level | $13.41 | $10.09 |
| Resistance Level | $14.76 | $10.33 |
| Average True Range (ATR) | 0.58 | 0.47 |
| MACD | -0.08 | 0.03 |
| Stochastic Oscillator | 11.29 | 40.83 |
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
Youdao Inc develops and markets software applications. It engages in developing technologies to provide learning content, applications, and solutions. The firm operates in three segments: Learning services, Smart devices, and Online marketing services. The majority of its revenue comes from the Learning services segment, which generates revenues from online courses, mainly including Youdao Premium Courses, NetEase Cloud Classroom, and China University MOOC. The learning products segment includes sales of smart devices such as the Youdao Dictionary Pen and the Youdao Pocket Translator. Geographically, all of its revenue is generated from the People's Republic of China.